A FLEDGLING BUT PROMISING form of immunotherapy known as CAR T cell therapy has been adapted to hit a new biologic target in the hopes that it will effectively fight advanced pancreatic cancer.
The technique is being tested in a phase 1 trial designed to enroll up to 30 patients with the disease. Read more . . .